Epic Sciences (United States)

Recent papers from Epic Sciences (United States)

1. Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and ImmunotherapyJournal of Nuclear Medicine · 2026
2. Polymeric mitral valve replacement in rheumatic heart disease: hemodynamic and early clinical outcomes from a dedicated sub-analysis of the India Surgical TrialFrontiers in Cardiovascular Medicine · 2026
3. Do Food Gardeners Value Food Differently? How Gardening Experience Shapes Consumer Preferences and Willingness to Pay for Organic and Local ProduceAgribusiness · 2026
4. Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trialClinical Cancer Research · 2026
5. Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169Clinical Cancer Research · 2026
6. ENVRI-Hub NEXT_D7.1_Report on Metadata Catalogue Development2026
7. ENVRI-Hub NEXT_D7.3_First Release of the Map-based User Interface2026
8. Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancerJCI Insight · 2025
9. Quantum Cognition Machine Learning for Forecasting Chromosomal Instability2025
10. Tetra-anionic porphyrin mimics protein-protein interactions between regulatory particles and the catalytic core, allosterically activating human 20S proteasomeJournal of Enzyme Inhibition and Medicinal Chemistry · 2025
11. Who Validates the Validators? Aligning LLM-Assisted Evaluation of LLM Outputs with Human Preferences2024
12. A novel liquid biopsy assay for detection of ERBB2 (HER2) amplification in circulating tumor cells (CTCs)Journal of Circulating Biomarkers · 2024
13. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b TrialEuropean Urology Oncology · 2024
14. Lost at SCLC: a review of potential platinum sensitizersCancer and Metastasis Reviews · 2024
15. Circulating tumor cells enumeration and characterization in patients with lung cancer treated with immunotherapy.Journal of Clinical Oncology · 2024
16. Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.Journal of Clinical Oncology · 2024
17. Abstract PO4-27-06: Design of Active Phase 3 ENABLAR-2 Study Evaluating Enobosarm +/- Abemaciclib in Patients with AR+ER+HER2- 2nd-Line Metastatic Breast Cancer Following Tumor Progression on an Estrogen Blocking Agent Plus Palbociclib or RibociclibCancer Research · 2024
18. Abstract PO4-06-12: Distinction of basal-like and triple-negative basal-like breast cancers utilizing a novel comprehensive single-cell liquid biopsy-based testCancer Research · 2024
19. Abstract PO5-04-05: Clinical validation of the concordance performance of ERBB2 status by single-cells genomics ERBB2 (HER2) amplification Assay in Circulating Tumor Cells (CTCs) from patients with matched HER2 status from metastatic tissue biopsiesCancer Research · 2024
20. Abstract PO1-17-07: Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative early breast cancer: a real-world analysisCancer Research · 2024